The MarketWatch News Department was not involved in the creation of this content. XTANDI is the first and only androgen receptor pathway inhibitor (ARPI) indicated and reimbursed in Ontario for use in ...
FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in ...
Adding enzalutamide (Xtandi) to androgen deprivation therapy (ADT) can extend metastasis-free survival while maintaining quality of life in men with prostate cancer who have a high risk for ...
(Reuters) - Use of Xtandi in early stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone, study ...
Talazoparib plus enzalutamide met the primary endpoint in TALAPRO-2, lowering radiographic progression or death risk by 37% versus enzalutamide, with median rPFS not reached. Efficacy signals extended ...
- If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient populations in ...
Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without sacrificing quality of life in prostate cancer. In patients with high-risk ...
The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to ...
The Food and Drug Administration approved Xtandi for non-metastatic castration-sensitive prostate cancer at high risk for biochemical recurrence. The Food and Drug Administration (FDA) approved Xtandi ...
May 25, 2012 (Atlanta) — A first-in-class drug, the androgen-receptor signaling inhibitor enzalutamide (MDV3100), has shown a survival benefit in men with postdocetaxel prostate cancer. The risk for ...
Lupin Ltd has received tentative approval from the USFDA for its generic enzalutamide tablets used to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results